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Edited by Vladimir SkulachevAbstract Chemotherapeutic drugs that inhibit the synthesis of
DNA precursor thymidine triphosphate cause apoptosis, al-
though the mechanism underlying this process remains rather
unknown. Here, we describe thymineless death of human myeloid
leukemia U937 cells treated with the thymidylate-synthase
inhibitor 50-ﬂuoro-20-deoxyuridine (FUdR). This apoptotic pro-
cess was shown to be independent of p53, reactive oxygen species
generation and CD95 activation. Caspases were activated
downstream of cytochrome c but upstream of mitochondrial
depolarization. Furthermore, FUdR-induced apoptosis required
the presence of glucose in the culture medium at a step upstream
of the release of cytochrome c from mitochondria.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A balanced supply of deoxyribonucleoside triphosphates
(dNTP) is essential for cell viability and replication. Pertur-
bations of the dNTP pools aﬀect genetic stability [1] and cause
cell death [2,3]. Several human diseases like anemia caused by
folate deﬁciency or immunodeﬁciency due to the lack of
adenosine-deaminase occur as a consequence of a non-bal-
anced supply of dNTPs in hematopoietic cells. Several
evidences link metabolism of dNTP and apoptosis. First, anti-
neoplastic agents that inhibit dNTP synthesis have been shown
to kill tumor cells by induction of apoptosis [4]. Second, dATP
may be essential for activation of the apoptosome [5], and the
mitochondrial dATP/ATP transporter adenine nucleotide* Corresponding author. Present address: La Jolla Institute for Allergy
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Abbreviations: ANT, adenine nucleotide translocator; dNTP, deoxy-
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-deoxyuridine; PBS, phosphate-buﬀered saline; dTTP, deoxythymi-
dine-triphosphate; DWm, mitochondrial membrane potential; FBS,
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BSO, L-buthionine-(S,R)-sulfoximine; ROS, reactive oxygen species;
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Permeability Transition Pore Complex, that may be involved
in the onset of apoptosis in several systems [6]. Third, changes
in dNTP levels have been found to precede DNA fragmenta-
tion in apoptosis driven by starvation of the survival factor
interleukin-3 [7].
‘‘Thymineless death’’ is observed in mammalian cells when
severe deoxythymidine-triphosphate (dTTP) depletion takes
place due to mutations or drug treatments. In this respect,
dTTP-depleting drugs such as methotrexate or 5-ﬂuorouracil
(5-FU) are currently being used in chemotherapy [8], although
the mechanism of dTTP depletion-induced apoptosis remains
to be elucidated. These drugs cause a decrease in dTTP levels
and a concomitant increase in dUTP, which can get incorpo-
rated into DNA. This would lead to extensive DNA damage as
a result of the active process of excision repair at the many
uracil-containing sites in DNA [9,10], and thus trigger a DNA-
damage induced pathway of apoptosis. Alternatively, pertur-
bation of dNTP pools might induce a mitochondrial pathway
of apoptosis by a direct eﬀect on mitochondrial nucleotide
translocators such as ANT, or by perturbation of mitochon-
drial nucleotide metabolism. This hypothesis is supported by
observations of a direct eﬀect of nucleotide analogs on mito-
chondria [11]. Several groups, including ours [4,12,13], have
demonstrated that over-expression of the anti-apoptotic pro-
tein Bcl-2 prevents the induction of apoptosis by inhibitors of
thymidylate synthesis. Bcl-2 inhibits apoptosis without aﬀect-
ing the depletion of dTTP, thus indicating a role of mito-
chondria in the execution of apoptosis [12].
Recent studies show that apoptosis induced by chemother-
apeutic drugs is blocked in ATP-depleted cells, both in vitro
[14] and in vivo [15]. The ATP-dependent step remains to been
determined. Although DNA damage-induced caspase activa-
tion does not occur under conditions of ATP depletion, the
initial steps of sensing DNA damage are unaﬀected [16]. It has
been suggested that the requirement of ATP may be due to its
stimulatory eﬀect of Apaf-1 in the apoptosome [14]. It is not
known whether apoptosis triggered by inhibition of thymi-
dylate-synthase requires ATP-generating systems.
In this report, we analyzed the mechanism of apoptosis in-
duced by the thymidylate-synthase inhibitor 50-ﬂuoro-20-de-
oxyuridine (FUdR) in human leukemic p53-negative U937
cells. Requirement of caspase-8 and eﬀector caspases, ordering
of caspase activation and mitochondrial events, production of
reactive oxygen species (ROS), and requirement of exogenous
glucose as supplier of ATP for the induction of apoptosis were
examined.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents
Caspase inhibitor benzyloxycarbonyl-Val–Ala–Asp-(OMe) ﬂuo-
romethyl ketone (Z-VAD-FMK) was purchased from Bachem. IETD-
FMK was from Enzyme System Inc. L-Buthionine-(S,R)-sulfoximine
(BSO) was a generous gift of Dr. Isabel Fabregat, Universidad Com-
plutense (Madrid). All other reagents were purchased from Sigma–
Aldrich Quimica, Spain.
2.2. Cell cultures
Human myeloid leukemic U937, THP-1 and HL-60 cells were
maintained in RPMI medium (Gibco) containing 10% fetal bovine
serum (FBS, Gibco), 1 mM glutamine and gentamycin, at 37 C in
a humidiﬁed 5% CO2/95% air incubator. Incubation under glucose-
free conditions was performed by washing cells twice in glucose-free
RPMI 1640 medium and incubating them in the same medium with
1 mM glutamine, 2 mM pyruvate and 1% dialyzed fetal bovine
serum. Control cultures were incubated with 2 g/l glucose instead of
pyruvate.
2.3. Analysis of viability and apoptosis
Hypodiploid apoptotic cells were detected by ﬂow cytometry ac-
cording to published procedures [17]. For analysis of membrane per-
meability in Table 1, cells were incubated with 5 lM propidium
iodide (PI) in PBS for 15 min and ﬂuorescence was detected by ﬂow
cytometry.
2.4. Measurements of mitochondrial depolarization and reactive oxygen
species (ROS)
For mitochondrial depolarization determinations, cells were col-
lected by centrifugation and resuspended in PBS with 40 nM 3,30-di-
hexyloxacarbocyanine iodide (DiOC6(3), Molecular Probes) and 5 lM
PI, and incubated for 15 min at room temperature. Generation of ROS
was quantiﬁed by adding 5 lm of H2DCFDA (dichlorodihydroﬂuo-
rescein diacetate, Molecular Probes) to the culture media for the last 30
min of treatment. Quantitative analysis of low DWm (mitochondrial
membrane potential) population and ROS production was carried out
in a FACScan cytometer using the Cell Quest software.
2.5. Immunoblot analysis of proteins
Preparation of cell lysates and analysis of proteins were performed
as described [18]. Antibodies used were: Mouse anti-b-tubulin mAb
(Sigma–Aldrich), mouse anti-human caspase-8 mAb (Cell Diagnostica,
M€unster, Germany); rabbit anti-cleaved caspase-3 polyclonal antibody
(New England BioLabs Inc), goat polyclonal anti-caspase-3 p20 (Santa
Cruz Biotech), mouse monoclonal antibodies to cytochrome c and Bax
(clone 6A7) (Pharmingen). For measurement of Cytochrome c release
and Bax translocation, cells were lysed and cytosolic fractions were
separated from mitochondria and nuclei as previously described [17].
Equal protein loading in each lane was veriﬁed by incubating mem-
branes with b-tubulin antibody.
2.6. Statistical analysis
Potential diﬀerences between treatments were evaluated using the
two tailed unpaired Student’s t test. Changes were considered signiﬁ-
cant when P < 0:05.Table 1
Production of ROS and FUdR-induced death in cells depleted of glutathion
ROS (fold induction of
mean ﬂuorescence)a
PI
(av
Untreated 1 1.
FUdR 1.8 0.7 23.
BSO 2.3 0.8 1.
BSO+FUdR 4.1 0.5 22.
Cells were treated as described in legends for Fig. 3(b).
aROS production is expressed as the fold increase in the ﬂuorescence of cells
untreated cells incubated with H2DCFDA in each experiment. Data show a
bCells were collected and subjected to analysis of PI incorporation and subG1
three experiments are shown.3. Results and discussion
3.1. 50-Fluoro-20-deoxyuridine induces caspase-dependent
apoptosis in human leukemic p53-negative cells
Despite the fact that drugs that inhibit dTTP metabolism are
currently used in chemotherapy, the mechanism involved in
dTTP depletion-induced apoptosis (thymineless death) is ra-
ther unknown. Tumor suppressor p53 has been often associ-
ated with death induced by inhibitors of dTTP synthesis, both
in vitro [19,20] and in vivo [21]. In contrast, p53-independent
apoptosis has been reported in colon cancer cell lines [22], and
we have previously shown that in a bone marrow-derived he-
matopoietic cell line, prevention of FUdR-induced p53 accu-
mulation does not lead to inhibition of death [23]. We
observed that several human myeloid leukemic cells (HL-60,
THP-1 and U937), which do not express p53 [24], undergo
apoptosis when treated with the thymidylate synthase inhibitor
FUdR, as measured by subG1 peak generation (Fig. 1(a)).
Diﬀerential requirement for p53 in response to dTTP-depleting
drugs may be cell-type speciﬁc or reﬂect diﬀerent mechanisms
of action of each drug. In this respect, disruption of p53 in
colon cancer cell lines has been shown to inhibit death induced
by 5-FU but not by two other inhibitors of thymidylate syn-
thase, methotrexate and Tomudex [25]. This indicates that
some of these drugs such as 5-FU may have other cellular
targets than thymidylate synthase, and that these other eﬀects,
such as perturbation of RNA metabolism, may be responsible
for the p53-dependence. Indeed, death induced by 5-FU can be
prevented by the addition of exogenous uridine but not by
thymidine [21,25], while apoptosis induced by speciﬁc inhibi-
tion of thymidylate-synthase is prevented by exogenous thy-
midine [26]. As shown in Fig. 1(a), apoptosis induced by
FUdR in leukemic cells was prevented by addition of thymi-
dine (20–50 lM) to the culture medium. In contrast, addition
of uridine did not protect U937 cells from apoptosis, indicating
that FUdR acts directly by inhibiting thymidilate-synthase
activity in p53-negative cells.
Several reports have described the pair CD95–CD95L as
critical mediators of thymineless death. CD95L messenger
RNA is upregulated in response to dTTP depletion in colon
carcinoma cells and a CD95-blocking mAb completely pre-
vents thymineless death in these cells [27]. However, we and
others have reported that apoptosis induced by inhibition of
thymidylate-synthase is not prevented by inhibiting ligation of
CD95 receptors by CD95L [22,23,28,29]. In U937 cells, we
could not ﬁnd any induction of CD95-ligand after treatment
with FUdR (not shown), suggesting that in this case, the paire
incorporation (%)
erageS.D.)b
Apoptosis (% subG1)
(averageS.D.)b
2 0.2 4.5 0.7
0 4.2 46.5 4.9
4 0.3 5.8 3.2
3 1.1 47.5 7
incubated with H2DCFDA, compared to the mean ﬂuorescence of the
verage and range of two experiments.
peak as described under Section 2. Averages and standard deviation of
Fig. 1. FUdR induces apoptosis in p53-negative cells. (a) HL-60, THP-1
and U937 cells were incubated at a density of 5 105/ml and treated
with FUdR (0.4 lM) for 15h in the presence of thymidine (T) or uridine
at the concentrations shown. SubG1 population was measured. The
average and standard deviation of at least three independent experi-
ments are shown. In (b), processing of procaspase-8 is shown. Intact
procaspase-8 and the intermediate cleavage products of 41/43 kDa were
detected. Cells were pre-incubated for 1 h in the presence of IETD-fmk
(100 lM) and subsequently treated with FUdR or 50 ng/ml anti-CD95
CH-11 mAb (Upstate Biotechnology) for 15 h before determining the
processing of procaspase-8. Unt, untreated. Result shown is represen-
tative of three independent experiments. (c) Cells were pre-incubated
for 1 h in the presence of either DMSO (0.2%), Z-VAD-fmk (100 lM)
or IETD-fmk (100 lM) and further treated for 15 h with FUdR (0.4
lM) or anti-CD95 (50 ng/ml). Apoptosis was measured as percent of
subG1 population. Results show average and S.E.M. of three inde-
pendent experiments. Asterisk indicates signiﬁcant inhibition.
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by thymidylate-synthase inhibition. It has been reported,
however, that certain genotoxic treatments may cause ligand-
independent CD95 receptor activation and apoptosis [30].
Also, several groups have reported the activation of caspase-8
in drug-induced apoptosis [31–34]. In some of these cases,
caspase-8 was cleaved through a re-ampliﬁcation loop in-
volving cytochrome c release from mitochondria and caspase-3
activation. To examine this issue, we ﬁrst studied the re-
quirements for caspase activation upon treatment of U937 cells
either with FUdR or with CD95 agonistic antibody. Time
course experiments of procaspase-8 processing demonstrated
that this procaspase was cleaved in response to FUdR with
similar kinetics to induction of apoptosis (not shown). We then
used cell-permeable caspase inhibitors in order to test whether
this caspase was required for FUdR-triggered death. As shown
in Fig. 1(b), pre-incubation of U937 cells with the caspase-8
inhibitor IETD-fmk completely blocked the processing of
caspase-8 by a subsequent treatment with FUdR or CD95
mAb. However, whereas induction of apoptosis by CD95 li-
gation was signiﬁcantly inhibited by both IETD-fmk and the
broad range caspase inhibitor Z-VAD-fmk, apoptosis trig-
gered by dTTP depletion was markedly inhibited by Z-VAD-
fmk but not by IETD-fmk (Fig. 1(c)). These results indicate
that the processing of procaspase-8 induced by treatment with
FUdR does not play an essential role in death of the cells.3.2. Caspase inhibitors prevent mitochondrial depolarization,
but not cytochrome c release upon dTTP depletion in U937
cells
Mitochondria play an important role in many models of
apoptosis [35,36]. In anti-CD95 induced apoptosis of type II
cells, activated caspase-8 cleaves Bid which translocates to
mitochondria and induces release of cytochrome c and mito-
chondrial depolarization [37,38]. However, in genotoxic drug-
induced apoptosis, the pathway to cytochrome c release has
not been determined. Mitochondria are involved in apoptosis
induced by thymidylate-synthase inhibition in diﬀerent cell
types, as Bcl-2 protects hematopoietic cells from FUdR-in-
duced apoptosis [12] and FUdR triggers cytochrome c release
in breast cancer cells [29]. We observed that overexpression of
Bcl-2 protected U937 cells from FUdR-triggered apoptosis
(not shown). We next determined whether FUdR triggered
cytochrome c release and mitochondrial depolarization in
U937 cells. As shown in Fig. 2(a), cytochrome c was released
from mitochondria in cells treated with FUdR or anti-CD95.
Both Z-VAD-fmk and IETD-fmk blocked cytochrome c re-
lease in anti-CD95 treated cells but not in FUdR-treated cells
(Fig. 2(a)). These results suggest that while caspase activation
is required for cytochrome c release in death receptor-induced
death, this is not the case in cells treated with FUdR, in
agreement with previous results obtained with other DNA-
damaging drugs [34].
Cytochrome c may be released in some cases as a conse-
quence of mitochondrial permeability transition [39]. In these
cases, mitochondrial depolarization occurs before cytochrome
c release and is not prevented by caspase inhibition. However,
in other instances cytochrome c release appears to trigger
caspase activation and mitochondrial depolarization [40]. In
Fig. 2(b), we show that U937 cells treated either with FUdR
or anti-CD95 underwent mitochondrial depolarization.
Fig. 2. Caspase inhibitors prevent mitochondrial depolarization but
not cytochrome c release in FUdR-induced apoptosis. U937 cells were
pre-incubated for 1 h with caspase inhibitors (100 lM) and treated
subsequently for 15 h with FUdR (0.4 lM) or anti-CD95 (50 ng/ml). In
(a), cytosolic fractions of treated cells were blotted for cytochrome c.
Equal loading of protein was veriﬁed by incubation of the membrane
with anti-tubulin (not shown). A representative experiment from at
least three independent determinations is shown. In (b), cells were
pre-incubated with Z-VAD-fmk and collected after treatments for
measurement of mitochondrial depolarization. Depolarization was
analyzed as described under Section 2. Percent of PI-negative cells with
depolarized mitochondria is shown. Results show average and range of
two independent experiments.
Fig. 3. Generation of ROS and translocation of Bax to the mito-
chondrial fraction after treatment with FUdR. In (a), cells were in-
cubated with FUdR 0.4 lM for the indicated times, and collected and
subjected to fractionation as described under Section 2. Immunode-
tection of cytochrome c and Bax in cytosolic and heavy-membrane
fractions is shown. In (b), cells were treated with 0.4 lM of FUdR for
15 h, in the presence or absence of BSO 2 mM, and incubated for 30
min with H2DCFDA as described under Section 2.
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ished mitochondrial depolarization caused by a subsequent
treatment with FUdR or anti-CD95. This indicates that in
both apoptotic situations, mitochondrial depolarization occurs
as a consequence of caspase activation, in agreement with
other results [40,41]. Altogether, these results also demonstrate
that unlike what is observed in CD95-activated apoptosis, re-
lease of cytochrome c from mitochondria upon FUdR treat-
ment can be dissociated from the induction of mitochondrial
depolarization. It has been reported that drug-induced, p53-
mediated apoptosis proceeds through Bax translocation to
mitochondria [42]. However, little is known about the mech-
anism of genotoxic drug-induced apoptosis in p53-negative
cells. We show in Fig. 3(a) that treatment with FUdR caused
Bax disappearance from cytosolic fractions and translocation
to the heavy membrane fraction, concomitantly with cyto-
chrome c release from mitochondria. Although we were not
able to demonstrate a cause-eﬀect relationship between these
two events, both events occurred within the same time range,
suggesting a possible role of Bax translocation to mitochon-
dria in the release of cytochrome c from this organelle in a p53-
independent manner.
3.3. Reactive oxygen species do not mediate FUdR-induced
apoptosis
It has been proposed that drug-induced, p53-mediated ap-
optosis proceeds through alterations in redox metabolism [43].
Furthermore, it was recently described that in the cell line used
in our studies, death induced by alkylating agents requiredproduction of ROS [44]. To our knowledge, there are no
studies on the relationship of thymineless death and generation
of ROS. We wished to test whether inhibition of thymidylate-
synthase caused induction of ROS, and whether this produc-
tion was involved in cell death. For this purpose, we analyzed
the production of peroxides by measuring H2DCFDA oxida-
tion and we observed that FUdR caused the production of
ROS (Fig. 3(b) and Table 1). To analyze whether production
of ROS was involved in FUdR-induced death, we performed
two types of experiments. First, we treated cells with FUdR in
the presence of the antioxidants N-acetyl-L-cysteine (up to 10
mM) and pyrrolidine dithiocarbamate (up to 50 lM), and we
observed no diﬀerences in apoptosis (not shown). Second, we
depleted cells of reduced glutathione by adding L-buthionine-
(S,R)-sulfoximine (BSO) to culture medium and we subse-
quently treated them with FUdR. BSO has been shown to
enhance death of U937 cells treated with alkylating agents [44].
As shown in Table 1, although pretreatment with BSO en-
hanced the production of ROS by FUdR, the number of dead
cells did not change, as measured by PI incorporation and
subG1 analysis. These results indicate that apoptosis induced
by inhibition of thymidylate-synthase does not require pro-
duction of Reactive Oxygen Species.
3.4. Glucose deprivation reduces FUdR-induced but not
CD95-triggered apoptosis
Apoptosis is an active process that may require ATP for its
correct development. ATP seems to be necessary for drug-in-
duced death in vivo, as an inhibitor of glucose uptake inhibits
doxorubicin-triggered death [15], and in vitro, incubation of
Jurkat cells in glucose-free medium in the presence of oligo-
mycin inhibits apoptosis triggered by several chemotherapeutic
drugs [14]. In order to test whether ATP was required for
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incubating cells in glucose-free medium, as we had previously
observed that U937 cells depend mainly on glucose supply in
order to maintain ATP levels [45]. By using this approach, we
avoided the use of oligomycin, that may interfere with the
mechanism of apoptosis by preventing cytosol acidiﬁcation,
cytochrome c release and Permeability Transition related
events [46,47]. When cells were pre-incubated in the absence of
glucose, apoptosis induced by FUdR was reduced (Fig. 4(a)).
In contrast, anti-CD95-triggered apoptosis was enhanced by
glucose deprivation, as we have previously shown [45]. It has
been suggested that ATP depletion may aﬀect drug-induced
apoptosis by inhibiting the activation of Apaf-1 at the apop-Fig. 4. Glucose withdrawal reduces FUdR-induced but not anti-CD95-
triggered apoptosis. Cells were pre-incubated for 3 h in the absence of
glucose with 1% FBS, as described in Section 2, and further treated for
13 h with FUdR (0.4 lM) or anti-CD95 (50 ng/ml). In (a), apoptosis
was measured as percent of subG1 population. Results show average
and S.E.M. of ﬁve independent experiments. (b) Analysis of caspase
activation by western blotting. Active p17 subunit of caspase-3 and
p18 fragment of caspase-8 are shown. Unt, untreated. Results shown
are representatives of three independent experiments. (c) Percent of PI-
negative cells with depolarized mitochondria is shown. Results show
average and S.E.M. of three independent experiments. In (d), cytosolic
fractions of treated cells were analyzed for the presence of cytochrome
c. Equal loading of protein was veriﬁed by incubation with anti-tubulin
(not shown). Unt, untreated cells; F, treated with FUdR; CD95,
treated with anti-CD95. Results shown are representatives of three
independent experiments. Asterisks indicate signiﬁcant diﬀerences with
respect to the glucose-replenished conditions.tosome, that requires ATP or dATP as well as cytochrome c
for the activation of caspase-9 [14]. To determine the step in
the apoptotic pathway that requires the presence of glucose in
the medium, we analyzed several apoptotic parameters in cells
treated either with anti-CD95 or FUdR under conditions of
glucose starvation. Cleavage of caspase-3 and -8 correlated
with the extent of apoptosis induced by these stimuli under
conditions of glucose starvation (Fig. 4(b)), activation of these
caspases was clearly reduced upon FUdR treatment in glucose-
free medium; however, caspase activation in CD95 Ab-treated
cells was not diminished by glucose depletion. Consistent with
the results shown in Figs. 2(b) and 4(b), the extent of depo-
larization was reduced when cells were treated with FUdR
under conditions of glucose starvation (Fig. 4(c)). Finally, we
analyzed the release of cytochrome c induced either by FUdR
or anti-CD95 Ab in glucose-free medium. As shown in
Fig. 4(d), cytochrome c release was clearly inhibited in glucose-
free medium when cells were treated with FUdR but not when
treated with anti-CD95. These results indicate that glucose is
required for FUdR-induced apoptosis at least at a mitochon-
drial or pre-mitochondrial step. Why ATP or glucose catab-
olism is required for drug-induced apoptosis but not for death
caused by anti-CD95 is an issue that requires further attention,
especially if we want to speculate with the therapeutical pos-
sibilities of a selective modulation of the diﬀerent apoptotic
signaling pathways. Some of these genotoxic drugs require
progression through the cell cycle in order to cause DNA-
damage and apoptosis. A possibility that has not been tested,
to our knowledge, is that glucose removal may delay or inhibit
cycling of cells, and this could aﬀect drug- but not anti-CD95-
induced apoptosis. As we have shown, one of the upstream
common steps in apoptosis induced by most genotoxic drugs,
cytochrome c release, is prevented in glucose-free medium.
Then, the point of inhibition must aﬀect the largely unchar-
acterized signals that link damage-sensing to mitochondrial
events.
In summary, our data may contribute to an understanding
of the mechanism of ‘‘thymineless death’’, particularly in
those aspects concerning the relationship between caspase
activation, mitochondrial events and requirement of glucose/
ATP. They may also help in the design of combination
treatments to improve present therapeutic approaches to
human neoplasias based on the use of drugs inhibiting dNTP
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